BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...

The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...

In an interview on Friday, FDA Commissioner Marty Makary threw his weight behind psychedelic therapies, noting that patients ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...